OncoMatch/Clinical Trials/NCT06228079
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Is NCT06228079 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Immunotherapy,Toripalimab and Chemotherapy,Gemcitabine based regimen for recurrent nasopharyngeal carcinoma.
Treatment: Immunotherapy,Toripalimab · Chemotherapy,Gemcitabine based regimen — Adjuvant Therapy Versus Endoscopic Surgery Alone in Early-stage Recurrent Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Trial
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RT1, RT2, RT3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy
previously radiotherapy for only 1 course
Must have received: surgery
Undergone endoscopic surgery with negative pathological margin
Cannot have received: radioactive particle planting
History of radioactive particle planting
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify